Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00535665 | Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine | PHASE2 | COMPLETED | 402 | — | — | Sep 1, 2007 | Nov 1, 2007 | Nov 9, 2007 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1: 10 ug, 14 days | EXPERIMENTAL | - |
| 2: 5 ug, 28 days | EXPERIMENTAL | - |
| 3: 10 ug, 28 days | EXPERIMENTAL | - |
| 4: 15 ug, 28days | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| pandemic influenza vaccine (H5N1 strain NIBRG-14) | BIOLOGICAL | two-dose regimen with 14 days apart: 5 microgram per dose |
Inclusion Criteria: * Healthy adults aged 18-60 years old * Be able to show legal identity card for the sake of recruitment * Be able to understand and sign the informed consent. Exclusion Criteria: * Woman： Who breast-feeding or planning to become pregnant during the 56 days of study participati...